Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tudor-Eliade Ciuleanu

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
The Lancet. Oncology|December 17, 2013
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialCharles Butts, Mark A Socinski, Paul L Mitchell, et al.
Nature Cancer|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trialSolange Peters, Daniel S W Tan, David E Gerber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled AnalysisSolange Peters, Luis G Paz-Ares, Martin Reck, et al.
Cancer Treatment and Research Communications|December 13, 2025
Impact of patient and tumor characteristics on various aspects of the non-small cell lung cancer patient journey in Romania, Bulgaria, Serbia: A multicenter, non-interventional, retrospective cohort studyAlexandra C Preda, Rossitza Krasteva, Mihailo Stjepanović, et al.
Cancers|January 12, 2021
Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical TrialSalomon M Stemmer, Nebojsa S Manojlovic, Mihai Vasile Marinca, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Journal for Immunotherapy of Cancer|February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
The Lancet. Oncology|December 17, 2013
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialCharles Butts, Mark A Socinski, Paul L Mitchell, et al.
Nature Cancer|May 13, 2026
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trialSolange Peters, Daniel S W Tan, David E Gerber, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled AnalysisSolange Peters, Luis G Paz-Ares, Martin Reck, et al.
Cancer Treatment and Research Communications|December 13, 2025
Impact of patient and tumor characteristics on various aspects of the non-small cell lung cancer patient journey in Romania, Bulgaria, Serbia: A multicenter, non-interventional, retrospective cohort studyAlexandra C Preda, Rossitza Krasteva, Mihailo Stjepanović, et al.
Cancers|January 12, 2021
Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical TrialSalomon M Stemmer, Nebojsa S Manojlovic, Mihai Vasile Marinca, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Journal for Immunotherapy of Cancer|February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.
Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 7